CO6290702A2 - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos - Google Patents

Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Info

Publication number
CO6290702A2
CO6290702A2 CO10102866A CO10102866A CO6290702A2 CO 6290702 A2 CO6290702 A2 CO 6290702A2 CO 10102866 A CO10102866 A CO 10102866A CO 10102866 A CO10102866 A CO 10102866A CO 6290702 A2 CO6290702 A2 CO 6290702A2
Authority
CO
Colombia
Prior art keywords
replicate
alfavirus
recombinants
mosquitoes
attacked
Prior art date
Application number
CO10102866A
Other languages
English (en)
Spanish (es)
Inventor
Scott C Weaver
Iiya Frolov
Elena Frolova
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CO6290702A2 publication Critical patent/CO6290702A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CO10102866A 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos CO6290702A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24

Publications (1)

Publication Number Publication Date
CO6290702A2 true CO6290702A2 (es) 2011-06-20

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10102866A CO6290702A2 (es) 2008-01-24 2010-08-20 Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos

Country Status (15)

Country Link
US (3) US8426188B2 (enExample)
EP (2) EP2250269B1 (enExample)
JP (1) JP5758632B2 (enExample)
KR (2) KR101913790B1 (enExample)
CN (1) CN102083986B (enExample)
AU (1) AU2009238667A1 (enExample)
CA (2) CA2713165C (enExample)
CO (1) CO6290702A2 (enExample)
IL (2) IL207167A (enExample)
MX (3) MX378503B (enExample)
MY (1) MY178870A (enExample)
NZ (2) NZ587502A (enExample)
SG (2) SG187513A1 (enExample)
WO (1) WO2009131604A2 (enExample)
ZA (1) ZA201005943B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
JP5758632B2 (ja) 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
US9701719B2 (en) 2012-09-27 2017-07-11 Research Development Foundation Attenuated Chikungunya virus
US10137186B2 (en) 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
EP3436062A1 (en) * 2016-03-31 2019-02-06 Takeda Vaccines, Inc. Live, attenuated alphavirus constructs and methods and uses thereof
PH12018502460B1 (en) * 2016-05-27 2023-11-08 Univ Griffith Arthrogenic alphavirus vaccine
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
KR102823029B1 (ko) 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
US20210268098A1 (en) * 2018-08-03 2021-09-02 Uab Research Foundation Methods and compositions for alphavirus vaccine
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
KR102764120B1 (ko) 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
EP1658744A4 (en) 2004-07-30 2006-09-27 Research In Motion Ltd METHOD AND SYSTEM FOR COORDINATING THE PARAMETERS OF A DEVICE BETWEEN A COMMUNICATIONS CLIENT AND HOST DEVICE
US7332322B2 (en) * 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
JP5758632B2 (ja) 2008-01-24 2015-08-05 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用

Also Published As

Publication number Publication date
US9580690B2 (en) 2017-02-28
KR101913790B1 (ko) 2018-12-28
EP3085787B1 (en) 2020-10-28
US20140010841A1 (en) 2014-01-09
NZ603790A (en) 2014-08-29
CA2713165C (en) 2015-12-29
MX367792B (es) 2019-09-05
MX2019010530A (es) 2019-10-15
KR20100106599A (ko) 2010-10-01
JP5758632B2 (ja) 2015-08-05
EP2250269A4 (en) 2012-01-04
WO2009131604A2 (en) 2009-10-29
EP2250269A2 (en) 2010-11-17
NZ587502A (en) 2012-12-21
EP3085787A1 (en) 2016-10-26
KR101668849B1 (ko) 2016-10-24
MX2010007989A (es) 2010-12-21
CA2910235A1 (en) 2009-10-29
SG10201606111XA (en) 2016-09-29
US8426188B2 (en) 2013-04-23
CN102083986A (zh) 2011-06-01
US10533186B2 (en) 2020-01-14
ZA201005943B (en) 2011-04-28
IL232032A0 (en) 2014-05-28
EP2250269B1 (en) 2016-03-16
IL207167A0 (en) 2010-12-30
KR20160124255A (ko) 2016-10-26
US20110052634A1 (en) 2011-03-03
AU2009238667A1 (en) 2009-10-29
CN102083986B (zh) 2014-06-18
MY178870A (en) 2020-10-21
MX378503B (es) 2025-03-11
JP2011523347A (ja) 2011-08-11
CA2713165A1 (en) 2009-10-29
US20170240919A1 (en) 2017-08-24
WO2009131604A3 (en) 2009-12-23
IL207167A (en) 2014-04-30
CA2910235C (en) 2021-07-06
SG187513A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MX2019010530A (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
MX2024008058A (es) Adenovirus modificados.
UY37563A (es) Aislados de bacillus y usos de los mismos
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
CO6761348A2 (es) Compuestos antivirales
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
CO6420394A2 (es) Estructura tipo lamina insecticida para proteger seres humanos y animales domesticos
BR112014032910A2 (pt) solfactants de éter de glicerina etoxilado
MX370148B (es) Composiciones y su uso para inmunoterapia.
ECSP12011637A (es) Polipéptidos del factor ix modificados y usos de los mismos
PY1256860A (es) Mezclas pesticidas que incluyen pirrolidindionas espiroheterocíclicas
CU20110191A7 (es) Compuestos orgánicos y sus usos
CL2013000505A1 (es) Estructura fibrosa fijada y/o estabilizada de un material fibroso asi como un agente para su fijacion y estabilizacion, donde dicho agente es al menos un copoliester estadistico formado por: acido tereftalico, acido isoftalico, butanodiol, dietilenglicol, trietilenglicol; metodo de fabricacion; material compuesto de resina-fibra; y uso de dicha estructura.
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
BR112015011254A2 (pt) Utilização de um composto constituído por uma unidade de polifluorobenzilo contra pragas resistentes a inseticidas
AR083215A1 (es) Combinacion sinergica de abamectina y bifentrina, su proceso de preparacion y uso, y metodo utilizando la misma
NZ631012A (en) Compositions and methods for live, attenuated alphavirus formulations
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
BRPI0815913A8 (pt) Composição de misturas antioxidantes apropriadas para uso em biodiesel.
BR112013013960A8 (pt) Composi%c3%87%c3%95es de vacinas de mal%c3%81ria, polipept%c3%8ddeos, fragmentos do mesmo, mol%c3%89culas de %c3%81cido nucleico, e usos destes
BR112022016428A2 (pt) Uso de matriz extracelular placentária porcina descelularizada, estruturas porcinas e seus métodos de preparação
ECSP20071177A (es) 4-amino-6-(1,3-benzodioxol)picolinatos y su uso como herbicidas

Legal Events

Date Code Title Description
FG Application granted